Insights - Celgene (CELG) said on Wednesday morning that a phase 3 trial of Otezla, the company’s oral inhibitor of phosphodiesterase 4 (PDE4) already approved in active psoriatic … Continue Reading
Read NowInsights - Anacor (ANAC) received FDA approval for the antifungal Kerydin on Tuesday, setting it and the larger Valeant (VRX) up for a marketing battle.
Read NowInsights - Following an end-of-phase 2 meeting with the FDA, Synergy Pharmaceuticals (SGYP) will begin two phase 3 studies of plecanatide, the company’s lead drug candidate, in Irritable … Continue Reading
Read NowInsights - Since Mr. Deryugin suggested in December that BioDelivery Sciences (BDSI) would be delivering profits in 2014, this pick is up 175%.
Read NowInsights - Shares of Regado Biosciences (RGDO) fell 50% after the company reported an unplanned review of the ongoing REGULATE-PCI phase 3 trial of its novel anti-coagulant, Revolixys (previously … Continue Reading
Read NowInsights - There may be reason for investors to get comfortable with Tekmira's (TKMR) latest safety issue. Here's why.
Read NowInsights - Shares of biopharmaceutical company Zogenix, Inc. (ZGNX) are up 16% in trading on Wednesday after the company announced that a new, abuse-deterrent formulation of Zohydro … Continue Reading
Read Now
